Clinical Trial Update: Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Ezurpimtrostat with atezolizumab-bevacizumab as first-line therapy for unresectable hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• Ezurpimtrostat

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED